Increase in Malignancies as Cause of Death in Renal Transplant Patients

Mazuecos, Auxiliadora; Muñoz-Terol, José Manuel; Álvarez, Teresa; Sola, E.; Benot, Alberto Rodriguez; Dsuna, A.; Bedoya, Rafael; Gentil, M.A.

doi:10.1016/j.transproceed.2009.05.029

Cited by 23 publications

(23 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Response to the treatment decreased the incidence of death. Our estimates extended the findings of Mazuecos et al and Einollahi et al who reported that age and immunosuppressive treatment were related to cancer development (26, 30, 38) that increased mortality. Moreover, Alonso and Oliver showed in their study that post-transplant mortality was dependent on age in all recipients (39).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis

et al. 2014

View full text Add to dashboard Cite

Background:Malignancy is a common complication after renal transplantation. Death with functioning graft and chronic graft loss are two competing outcomes in patients with post-transplant malignancies.Objectives:The purpose of our study was to evaluate the risk factors associated with cumulative incidence of these two outcomes.Patients and Methods:Fine-Gray model was used for 266 cases with post-transplant malignancy in Iran. These patients were followed-up from the diagnosis until the date of last visit, chronic graft loss, or death, subsequently.Results:At the end of the study, as competing events, chronic graft loss and death with functioning graft were seen in 27 (10.2%) and 53 cases (19.9%), respectively, while 186 cases (69.9%) were accounted as censored. The incidence rate of death was approximately two-time of the incidence rate of chronic graft loss (8.6 vs. 4.4 per 100 person-years). In multivariate analysis, significant risk factors associated with cumulative incidence of death included age (P < 0.007, subhazard ratio (SHR) = 1.03), type of cancer (P < 0.0001), and response to treatment (P < 0.0001, SHR = 0.027). The significant risk factors associated with cumulative incidence of chronic graft loss were gender (P = 0.05, SHR = 0.37), treatment modality (P < 0.0001), and response to treatment (P = 0.048, SHR = 0.47).Conclusions:Using these factors, nephrologists may predict the occurrence of graft loss or death. If the probability of graft loss was higher, physicians can decrease the immunosuppressive medications dosage to decrease the incidence of graft loss.

show abstract

Section: Discussionsupporting

confidence: 90%

“…The causes of graft loss have also changed over the time; currently, DWFG and chronic rejection are the principal causes of graft loss (25, 26). …”

Section: Introductionmentioning

confidence: 99%

Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[49][50][51] Also, oncologic disease after transplantation is one of the major causes of death in transplant patients with a functioning graft. 52,53 Existing treatment protocols are lacking to protect the allograft as well as attack the malignancy simultaneously. 54 New immunosuppressive drugs in particular those who have the dual ability to suppress both transplantation rejection and cancer development are needed.…”

Section: Discussionmentioning

confidence: 99%

Arsenic Trioxide Induces T Cell Apoptosis and Prolongs Islet Allograft Survival in Mice

Gao

Jiang

et al. 2015

Transplantation

View full text Add to dashboard Cite

show abstract

“…Although Kasiske et al (2004) 10 reported the largest study (n = 35765) about the incidence rates of malignancies among first-time kidney recipients, however, living donor transplantation only accounted 24% all of them (i.e., n=8584). Furthermore, the other huge studies 11-16 only focused on deceased kidney transplantation.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran

Einollahi

Rahimi²,

Nourbala³

et al. 2012

J. Cancer

View full text Add to dashboard Cite

Malignancy is a common complication after renal transplantation. However, limited data are available on post-transplant malignancy in living kidney transplantation. Therefore, we made a plan to evaluate the incidence and types of malignancies, association with the main risk factors and patient survival in a large population of living kidney transplantation. We conducted a large retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all kidney transplantation in Iran during 22 years follow up period. All information was collected from observation of individual notes or computerized records for transplant patients. Two hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age of patients was 46.2±12.9 years, mean age at tumor diagnosis was 50.8±13.2 years and average time between transplantation and detection of malignancy was 50.0±48.4 months. Overall tumor incidence in recipients was 2%. Kaposis' sarcoma was the most common type of tumor. The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate analysis, the only independent risk factor associated with mortality was type of malignancy. This study revealed the lowest malignancy incidence in living unrelated kidney transplantation.

show abstract

Increase in Malignancies as Cause of Death in Renal Transplant Patients

Cited by 23 publications

References 6 publications

Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis

Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis

Arsenic Trioxide Induces T Cell Apoptosis and Prolongs Islet Allograft Survival in Mice

Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran

Contact Info

Product

Resources

About